{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Park Y"],"funding":["Ministry of Trade, Industry and Energy","Ministry of Science and ICT","Ministry of Food and Drug Safety","Korea Medical Device Development Fund","Ministry of Health and Welfare"],"pagination":["340-349"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8925944"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(2)"],"pubmed_abstract":["<h4>Background/aims</h4>The continuous flow left ventricular assist device (cf-LVAD) has improved the survival of chronic end-stage heart failure (HF) patients. Here we describe our clinical experience of the initial 50 LVAD patients from a single center.<h4>Methods</h4>A total of 50 patients underwent LVAD implantation as bridge to transplantation (BTT; n = 28, 56%), bridge to candidacy (BTC; n = 2, 4%), or as destination therapy (DT; n = 20, 40%) from 2012 to 2019. Pre-implant characteristics and clinical outcomes were compared between BTT/BTC and DT.<h4>Results</h4>The median age of patients was 67 years (range, 59 to 73). Men were more likely to receive LVAD (76% vs. 24%) than women. DT patients were older, had smaller body surface area, and worse laboratory profiles than BTT/BTC patients. There was no in-hospital mortality. During an average of 14 months (range, 8 to 23), the all-cause mortality was 22%. The first-year survival was 86 and 90% in BTT/BTC and DT groups, respectively. Hemorrhagic stroke was the most common cause (27%) of death. In the BTT/BTC group, 22 patients successfully underwent heart transplantation during median duration of 10 months (range, 7 to 14). The most common post-LVAD complication during the first year of LVAD implantation was major bleeding (44%). A significant proportion (76%) of patients experienced rehospitalization with gastrointestinal bleeding as the most common cause.<h4>Conclusion</h4>We describe short-term clinical outcome of LVAD patients from a single center for the first time in Korea. With the newer generation LVAD and a dedicated team approach, improved clinical outcomes of LVAD for end-stage HF are expected."],"journal":["The Korean journal of internal medicine"],"pubmed_title":["Clinical outcome in patients with end-stage heart failure who underwent continuous-flow left ventricular assist devices in a single center."],"pmcid":["PMC8925944"],"funding_grant_id":["KMDF_PR_20200901_0159","1711138313"],"pubmed_authors":["Kim D","Jeon ES","Park Y","Yang JH","Choi JO","Cho YH"],"additional_accession":[]},"is_claimable":false,"name":"Clinical outcome in patients with end-stage heart failure who underwent continuous-flow left ventricular assist devices in a single center.","description":"<h4>Background/aims</h4>The continuous flow left ventricular assist device (cf-LVAD) has improved the survival of chronic end-stage heart failure (HF) patients. Here we describe our clinical experience of the initial 50 LVAD patients from a single center.<h4>Methods</h4>A total of 50 patients underwent LVAD implantation as bridge to transplantation (BTT; n = 28, 56%), bridge to candidacy (BTC; n = 2, 4%), or as destination therapy (DT; n = 20, 40%) from 2012 to 2019. Pre-implant characteristics and clinical outcomes were compared between BTT/BTC and DT.<h4>Results</h4>The median age of patients was 67 years (range, 59 to 73). Men were more likely to receive LVAD (76% vs. 24%) than women. DT patients were older, had smaller body surface area, and worse laboratory profiles than BTT/BTC patients. There was no in-hospital mortality. During an average of 14 months (range, 8 to 23), the all-cause mortality was 22%. The first-year survival was 86 and 90% in BTT/BTC and DT groups, respectively. Hemorrhagic stroke was the most common cause (27%) of death. In the BTT/BTC group, 22 patients successfully underwent heart transplantation during median duration of 10 months (range, 7 to 14). The most common post-LVAD complication during the first year of LVAD implantation was major bleeding (44%). A significant proportion (76%) of patients experienced rehospitalization with gastrointestinal bleeding as the most common cause.<h4>Conclusion</h4>We describe short-term clinical outcome of LVAD patients from a single center for the first time in Korea. With the newer generation LVAD and a dedicated team approach, improved clinical outcomes of LVAD for end-stage HF are expected.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-26T04:03:17.571Z","creation":"2025-04-06T10:57:26.106Z"},"accession":"S-EPMC8925944","cross_references":{"pubmed":["34871480"],"doi":["10.3904/kjim.2021.088"]}}